Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Yunshengyan New Biotechnology
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Yunshengyan New Biotechnology is a Chinese biotechnology company focused on the discovery and development of innovative therapies for autoimmune and inflammatory diseases. The company specializes in targeting the IL-17 pathway, which is a critical driver in conditions such as psoriasis and atopic dermatitis. Their research efforts include the development of small molecule inhibitors and biologics designed to provide more effective and convenient treatment options for patients. By leveraging advanced drug discovery techniques, Yunshengyan aims to address significant unmet medical needs in the immunology space.
- Therapeutic areas
- ImmunologyDermatology
- Modalities
- Small moleculeAntibody
- Industry
- Biotech
Beyond the preview
Go deeper on Shanghai Yunshengyan New Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Yunshengyan New Biotechnology.